Browsing by Author "Valenzuela, Francisca"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
Item Artritis psoriásica: La elección del fármaco antirreumático biológico en la Ley Ricarte Soto(2020) Ibáñez, Sebastián; Valenzuela, Francisca; Valenzuela, OmarThe financial coverage granted by law in Chile for patients with psoriatic arthritis who require biological treatment is of paramount importance and a great advance. However physicians must be knowledgeable about the advantages and limitations of this therapy. The challenge of clinicians is to choose the drug with the greater odds of achieving therapeutic success, with less adverse events and lower costs for our health system. This article aims to help doctors to select the best biological treatment for a specific patient, trying to optimize its effectiveness, minimizing adverse effects, always looking for an efficient use of resources.Item Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?(2020) Ibáñez, Sebastián; Martínez, Oriela; Valenzuela, Francisca; Silva, Francisco; Valenzuela, OmarThe pandemic of the new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has urged the nations to an unprecedented world-wide reaction, including an accelerated exploration of therapeutic options. In the absence of a vaccine and specifically designed antivirals, the medical community has proposed the use of various previously available medications in order to reduce the number of patients requiring prolonged hospitalizations, oxygen therapy, and mechanical ventilation and to decrease mortality from coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine are among the proposed drugs and are the most widely used so far, despite the lack of robust evidence on their usefulness. The objective of this article is to review and discuss the possible role of these drugs in the therapy of COVID-19.Item Nuevas alternativas de tratamiento en espondilitis anquilosante y artritis psoriásica(2022) Ibáñez, Sebastián; Martínez, Oriela; Valenzuela, FranciscaEn la artritis psoriásica y espondiloartritis existe aún espacio para nuevos medicamentos, con distintos mecanismos de acción, que permitan personalizar mejor el tratamiento. El objetivo de esta revisión es facilitar al clínico la decisión de utilizar tofacitinib, upadacitinib, o guselkumab, nuevas alternativas de tratamiento dentro de la gran variedad de fármacos disponibles actualmente